Johnson & Johnson $JNJ Stock Position Lifted by Cypress Wealth Services LLC

Cypress Wealth Services LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 71.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 12,272 shares of the company’s stock after acquiring an additional 5,103 shares during the period. Cypress Wealth Services LLC’s holdings in Johnson & Johnson were worth $2,540,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Wellington Management Group LLP raised its position in shares of Johnson & Johnson by 3.8% during the 3rd quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company’s stock worth $4,789,914,000 after buying an additional 956,239 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Johnson & Johnson by 3.5% in the third quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company’s stock valued at $4,568,313,000 after acquiring an additional 835,146 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of Johnson & Johnson by 2.8% in the third quarter. Legal & General Group Plc now owns 19,450,064 shares of the company’s stock valued at $3,606,431,000 after acquiring an additional 532,790 shares in the last quarter. Amundi increased its stake in shares of Johnson & Johnson by 19.3% during the third quarter. Amundi now owns 13,354,936 shares of the company’s stock valued at $2,512,719,000 after acquiring an additional 2,163,838 shares during the period. Finally, Raymond James Financial Inc. raised its holdings in Johnson & Johnson by 7.3% during the third quarter. Raymond James Financial Inc. now owns 10,137,651 shares of the company’s stock worth $1,879,718,000 after purchasing an additional 690,887 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Royalty Pharma agreed to provide $500 million of R&D co‑funding for JNJ‑4804, a novel co‑antibody targeting IL‑23 and TNF; the deal de‑risks development costs, validates the program and accelerates immunology exposure for J&J. Royalty Pharma and J&J partner to develop autoimmune treatment Johnson & Johnson’s JNJ-4804 Deal Adds Weight To Immunology Story
• Positive Sentiment: J&J presented first randomized Phase 2 data for JNJ‑1900 (NBTXR3) in stage‑3 inoperable lung cancer at a major conference — early positive clinical readouts support the oncology pipeline and partner collaborations. NANOBIOTIX Announces Presentation of First Data
• Positive Sentiment: Johnson & Johnson MedTech shared favorable findings for the Impella CP device in left‑ventricular support at ACC, which may support near‑term MedTech revenue momentum and competitive positioning. Johnson & Johnson MedTech shares findings for Impella CP
• Positive Sentiment: Royal Bank of Canada reaffirmed an “outperform” rating and a $255 price target, providing analyst backing that supports upside expectations versus current levels. RBC reaffirmation / Benzinga
• Positive Sentiment: Multiple outlets highlighted J&J as a top dividend/defensive stock and noted an upcoming dividend increase window — this bolsters demand from income and defensive investors given J&J’s low beta and long dividend history. This is Why Johnson & Johnson is a Great Dividend Stock Dividend increases coverage
• Neutral Sentiment: Industry research forecasts growth in the non‑muscle invasive bladder cancer market and lists J&J among leading competitors — a positive long‑term market backdrop but not an immediate catalyst. Non‑Muscle Invasive Bladder Cancer Market report

Wall Street Analyst Weigh In

JNJ has been the subject of a number of research analyst reports. Leerink Partners upped their target price on Johnson & Johnson from $201.00 to $232.00 and gave the stock a “market perform” rating in a research report on Thursday, January 22nd. Bank of America reissued a “neutral” rating on shares of Johnson & Johnson in a research note on Monday, March 2nd. HSBC raised their target price on Johnson & Johnson from $265.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Morgan Stanley set a $253.00 target price on Johnson & Johnson in a report on Wednesday, March 18th. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $236.91.

Insider Activity

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 1,322 shares of the firm’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,251,310.02. The trade was a 4.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 30,142 shares of company stock worth $7,360,528. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

NYSE JNJ opened at $242.22 on Tuesday. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $251.71. The business’s fifty day moving average is $237.87 and its two-hundred day moving average is $211.39. The stock has a market capitalization of $583.40 billion, a P/E ratio of 21.92, a P/E/G ratio of 2.37 and a beta of 0.34. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The business had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 47.06%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.